Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fibroid Uterus Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

NCT03411980
View directory record Official record
Conditions
Uterine Fibroids, Endometriosis
Interventions
Vilaprisan (BAY1002670)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 23, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

NCT00290251
View directory record Official record
Conditions
Leiomyoma
Interventions
ulipristal acetate 20 mg, ulipristal acetate 10 mg, placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years to 50 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Sep 23, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Combined Vaginal Misoprostol and Perivascular Vasopressin

NCT03815344
View directory record Official record
Conditions
Leiomyoma, Laparoscopy, Uterine Myomectomy
Interventions
Standard, Standard-vaginal misoprostol
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 23, 2026, 5:30 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

NCT00735553
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 23, 2026, 5:30 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Questionnaire Study to Assess Quality of Life After Treatment of Fibroids

NCT00390494
View directory record Official record
Conditions
Leiomyoma
Interventions
Hysterectomy, Myomectomy, Uterine Fibroid Embolization
Procedure
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
35 Years to 50 Years · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2008 · Synced Sep 23, 2026, 5:30 PM EDT
Recruiting No phase listed Observational

Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)

NCT06135870
View directory record Official record
Conditions
Fibroid, Leiomyoma
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 23, 2026, 5:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lower Urinary Tract Infection (UTI) Evaluation in Women With Uterine Leiomyomata

NCT01123603
View directory record Official record
Conditions
Urinary Tract Infection, Leiomyoma
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
860 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 23, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

NCT01451424
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Miami Gardens, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Sep 23, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication

NCT00365989
View directory record Official record
Conditions
Uterine Leiomyoma, Uterine Fibroids
Interventions
ExAblate Enhanced Sonication
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
4
States / cities
La Jolla, California • Burlington, Massachusetts • Kalamazoo, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 23, 2026, 5:30 PM EDT
Completed No phase listed Observational

Postpartum Uterine Regression

NCT00341848
View directory record Official record
Conditions
Uterine Leiomyoma
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2019 · Synced Sep 23, 2026, 5:30 PM EDT
Recruiting Phase 4 Interventional

Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy

NCT07286188
View directory record Official record
Conditions
Fibroids, Uterine, Fluid Deficit, Hysteroscopy / Methods
Interventions
Misoprostol Tabets, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 23, 2026, 5:30 PM EDT
Completed Not applicable Interventional Results available

Sonography Guided Transcervical Ablation of Uterine Fibroids

NCT02228174
View directory record Official record
Conditions
Menorrhagia
Interventions
Intrauterine Ultrasound-Guided Radiofreq. Ablation System
Device
Lead sponsor
Gynesonics
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Denver, Colorado • Newark, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 23, 2026, 5:30 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

NCT00853567
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex, placebo
Drug · Other
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
17
States / cities
Anaheim, California • Los Angeles, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 23, 2026, 5:30 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution

NCT01581905
View directory record Official record
Conditions
Menorrhagia, Dysfunctional Uterine Bleeding, Leiomyoma, Pelvic Pain, Endometriosis
Interventions
Conventional Laparoscopic Hysterectomy (LH), Robot Assisted Hysterectomy
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 23, 2026, 5:30 PM EDT
Completed Not applicable Interventional Results available

Symphion® System In-Office Study

NCT02520414
View directory record Official record
Conditions
Uterine Leiomyomas, Endometrial Polyps
Interventions
Symphion® Bipolar Hysteroscopic Tissue Resection System
Device
Lead sponsor
Minerva Surgical, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 23, 2026, 5:30 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effect of Addition of Steroids on Duration of Analgesia

NCT04126824
View directory record Official record
Conditions
Uterine Fibroids, Adenomyosis
Interventions
Triamcinolone, Bupivacaine, Iohexol contrast
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Westwood, Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 23, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03751124
View directory record Official record
Conditions
Uterine Leiomyoma, Uterine Fibroids
Interventions
Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
72
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 23, 2026, 5:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Truclear on Patient Quality of Life

NCT02934789
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Hysteroscopic myomectomy with Truclear, Medical therapy
Procedure · Drug
Lead sponsor
All For Women Healthcare, Illinois
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 23, 2026, 5:30 PM EDT
Completed Not applicable Interventional Results available

Safety Study of ExAblate for the Treatment of Uterine Fibroids

NCT01142791
View directory record Official record
Conditions
Uterine Fibroids
Interventions
ExAblate
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 23, 2026, 5:30 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

a Study to Evaluate Adhesion Risk in Fertility Patients' Status Post Laparoscopic Myomectomy.

NCT01971060
View directory record Official record
Conditions
Uterine Fibroids, Infertility
Interventions
surgery utilizing V-Loc suture
Device
Lead sponsor
The Advanced Gynecologic Surgery Institute
Other
Eligibility
18 Years to 42 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 23, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Dexamethasone for Post Uterine Artery Embolization Pain

NCT04655144
View directory record Official record
Conditions
Leiomyoma
Interventions
Dexamethasone, Saline
Drug
Lead sponsor
University of Miami
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 23, 2026, 5:30 PM EDT
Terminated Not applicable Interventional Results available

Embozene Microspheres for Uterine Fibroid Embolization (UFE)

NCT01675011
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Embozene® Microspheres, Embosphere®
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
30 Years to 50 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Albany, New York • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Sep 23, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03886220
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Elagolix, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
45
States / cities
Birmingham, Alabama • Searcy, Arkansas • La Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 23, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03049735
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
76
States / cities
Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 23, 2026, 5:30 PM EDT